Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) ( Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce
Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder
– Company expects to initiate Phase 3 pivotal trial in late summer 2024 – – Phase 3 pivotal study to include 30 clinical sites across the United States and Europe with deep expertise in depression studies – – Pivotal trial designs incorporate elements to address functional unblinding – – Company to
Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
– Phase 3 multinational study of CYB003 expected to begin in late summer 2024 – – 30 clinical sites selected across the United States and Europe for Phase 3 CYB003 study – – 12-month efficacy results from Phase 2 study of CYB003 in MDD expected Q4 2024 – – Additional United States patent granted
Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to
Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
– Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) – – Clinical site selection complete for Phase 3 multinational
Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development
– Dr. Mahableshwarkar, a Board-Certified Psychiatrist, is an experienced pharmaceutical industry leader with decades of expertise in drug development – TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024
– Amir Inamdar, Chief Medical Officer, to appear on panel discussions on June 5 and June 8 – – Ellen James, Director, Clinical Development, to present abstract titled “SPL026 (DMT fumarate) in combination with SSRIs for patients with Major Depressive Disorder” on June 6, 2024 – TORONTO–(BUSINESS
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
TORONTO–(BUSINESS WIRE)– Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased to